Congratulations to Nanjing Leads Biolabs Co., Ltd. (9887.HK) on its Successful Listing

Congratulations to Nanjing Leads Biolabs Co., Ltd. (9887.HK) on its successful Listing on the Mainboard of HKSE on 25 July 2025

Nanjing Leads Biolabs Co., Ltd. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of new therapies in oncology, autoimmune, and other severe diseases.

With regard to this listing application, AVISTA Group is honored to be engaged in providing valuation services on share reform, ODI valuation; and valuation services related to financial reporting purposes such as share-based compensation, preferred shares and convertible bonds.

Congratulations again Nanjing Leads Biolabs Co., Ltd. (9887.HK) on its successful listing. The issue price of the shares is HKD35 per share, and the amount of funds raised is 1.29 billion HKD.